Featured Industry Spotlight

Aethlon

Aethlon Medical Australia: a new approach in cancer therapy

April 9, 2025

Aethlon Medical Australia: New Approach in Cancer Therapy Aethlon Medical Australia PTY LTD, a subsidiary…

Featured Industry Spotlight $Protected: Gilead agrees funding with Federal Government for Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for second-line treatment of relapsed or refractory large b-cell lymphoma (LBCL)(1,2)$

Protected: Gilead agrees funding with Federal Government for Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for second-line treatment of relapsed or refractory large b-cell lymphoma (LBCL)^(1,2)

December 3, 2024

This content is password protected. To view it please enter your password below: Password:

Industry Spotlight

Two studies reflect growing confidence in novel therapy for non-melanoma skin cancer

November 8, 2024

Non-melanoma skin cancer (NMSC) is the most common type of cancer. NMSC treatment can be…

Featured Industry Spotlight

Global teleradiology provider, Everlight Radiology, celebrates issuing over 15,000 CPD certificates to radiologists around the globe

September 30, 2024

Global teleradiology provider, Everlight Radiology, is pleased to announce that its core radiology education programme,…

Cancer Drug News $Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for adult relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r ALL)$

Protected: Tecartus^® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for adult relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r ALL)

June 20, 2024

This content is password protected. To view it please enter your password below: Password:

Cancer Drug News $Protected: Tecartus® (Brexucabtagene Autoleucel) CAR T-cell therapy now funded in Australia for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL)$